US Pharma MarketingLundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
The EC has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart for the treatment of Cushing’s syndrome of endogenous origin.
The EC has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart for the treatment of Cushing’s syndrome of endogenous origin.
Source: Pharmaceutical Technology